Dr. Hong on Comparing the Use of Sotorasib and Adagrasib in CRC

In Partnership With:

Partner | Cancer Centers | <b>MD Anderson</b>

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses data examining the use of sotorasib (Lumakras) and adagrasib (MRTX849) in colorectal cancer (CRC).

Both agents have appeared to generate increased response rates in CRC, Hong says. In the phase 1 CodeBreaK100 trial (NCT03600883), sotorasib demonstrated clinical activity in KRAS G12C-mutated solid tumors, including CRC. In the phase 1/2 KRYSTAL-1 trial (NCT03785249), adagrasib alone and in combination with cetuximab (Erbitux) yielded meaningful response rates in previously treated KRAS G12C-mutated CRC.

Further research will need to evaluate if these responses will lead to meaningful differences in progress-free survival and overall survival between the 2 agents, since these trials examined a small number of patients with a short follow-up, Hong explains. Notably, KRAS G12C inhibitors alone will not likely serve as tumor agnostic therapies, Hong concludes.